‌

CMHC West CME Symposia

Sunrise CME Symposium

Friday, August 7, 2020 · 7:00 – 8:15 AM

Challenging the Status-Quo: Cardiorenal Protection with SGLT-2 Inhibitors in T2DM and Beyond--Expert Debate and Discussions

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

Review the underlying links between CVD, HF, DKD, and T2DM and how the potential mechanisms of action of SGLT-2 inhibitors help address cardiorenal risk in T2DM and beyond.

Summarize recently-concluded and ongoing studies about the efficacy and safety of SGLT-2 inhibitors in addressing cardiometabolic risk in patients with and without T2DM.

Discuss practical approaches and strategies, including multidisciplinary collaboration, for the use of SGLT-2 inhibitors in T2DM patients with cardiorenal risk.

Develop individualized treatment regimens based on the latest evidence and guideline recommendations in order to address cardio-renal risk in patients with T2DM

This activity is jointly provided by Annenberg Center for Health Sciences at Eisenhower and CMHC in collaboration with Postgraduate Institute for Medicine. Supported by an educational grant from AstraZeneca.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC West 2020, please click here.

CME Sunrise Symposium

Saturday, August 8, 2020 · 7:00 – 8:15 AM

The Evolving Landscape of LDL-C Reduction: Novel Therapies and Approaches

Chaired by: Christie M. Ballantyne, MD

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

Recognize residual ASCVD risk that may persist even after maximally-tolerated statin therapy, ezetimibe, or PCSK9-inhibiting mAbs

Identify high-risk patients with elevated LDL-C and ASCVD who may not adequately respond or adhere to current therapy

Review the rationale, mechanisms of action, efficacy and safety of LDL-C lowering agents in advanced clinical development and their potential role in hypercholesterolemia management and ASCVD risk reduction

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from Esperion Therapeutics, Inc..

CME Satellite General Session

Saturday, August 8, 2020 · 3:30 – 4:10 PM

Update on Antiplatelet and Antithrombotic Therapy in the Cardiometabolic Patient

Presented by: Roxana Mehran, MD

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

Define the association between diabetes and increased thrombotic risk and adverse events in patients with CAD and PAD.

Interpret the results of recently concluded clinical trials about the efficacy and safety of novel antithrombotic approaches in patients with diabetes and concomitant CAD and PAD to inform treatment decisions.

A division of Tarsus Medical owned by Tarsus Group

Medical Website Design and Medical SEO by WebToMed